Oct 24, 2019 / 10:30AM GMT
Raj Kumar Shreeram Baheti - Alembic Pharmaceuticals Limited - Director of Finance, CFO & Executive Director
Thank you very much. Good evening, everyone. Thank you all for joining the Second Quarter Results Conference Call. I'm sure you would have got all the results by now and our press release and the investor presentation. However, let me briefly take you through the numbers for the quarter ended 30th of September 2019, and obviously, the H1 of 2019 -- '19-'20.
During the quarter, the total revenue grew by 10% to INR 1-2-4-1 crores, INR 1,241 crores. EBITDA at INR 342 crores, [each] 28% of sales, and it grew by 12% on Y-o-Y. Pre-R&D EBITDA is 41% of sales. Profit before tax went up by 10% to INR 299 crores, while the after-tax number, PAT, went up by 23% to INR 246 crores.
During the half year, the total revenue grew by 10% to INR 2-1-9-0 crores, INR 2,190 crores. EBITDA at INR 575 crores is 26% of sales, and it grew by 26% on Y-o-Y, H1 of this year versus H1 of last year, 26% growth. Pre-R&D EBITDA is 40% of sales. The net profit after exceptional items and tax went up by
Q2 2020 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Oct 24, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers